Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution.

T-cell receptor (TCR) with unique major histocompatibility complex (MHC)-unrestricted antigen-binding properties was isolated from a human T-cell clone specific for the tumor antigen MUC1. This TCR binds its epitope on the MUC1 protein without the requirement of processing and presentation. A single-chain Valpha/Vbeta/Cbeta (scTCR) was fused to a CD3 zeta (zeta) chain to allow expression on the surface of cells of the innate (granulocytes, macrophages, natural killer [NK] cells) as well as the adaptive (T and B cells) immune system. To test the ability of the cells of the innate immune system to reject a tumor when provided with a tumor antigen-specific TCR, we reconstituted severe combined immunodeficiency (SCID) mice with bone marrow cells transduced with a retroviral vector encoding this receptor and challenged them with a MUC1-positive human tumor. These mice controlled the growth of the tumor significantly better than the control mice. We performed a similar experiment in immunocompetent mice transgenic for human MUC1. Expression of the TCR on large percentages of cells did not result in infiltration or destruction of tissues expressing MUC1. Reconstituted mice controlled the outgrowth of a MUC1-transfected but not the parental control tumor. scTCR expression appears lifelong, suggesting a successful transduction of the self-renewing stem cells.

[1]  Irving L Weissman,et al.  Biology of hematopoietic stem cells and progenitors: implications for clinical application. , 2003, Annual review of immunology.

[2]  J. Bubeník.  Tumour MHC class I downregulation and immunotherapy (Review). , 2003, Oncology reports.

[3]  S. Rosenberg,et al.  High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens , 2003, The Journal of Immunology.

[4]  Z. Eshhar,et al.  Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. , 2003, Cancer research.

[5]  L. Otvos,et al.  Complex Carbohydrates Are Not Removed During Processing of Glycoproteins by Dendritic Cells , 2002, The Journal of experimental medicine.

[6]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  D. Baltimore,et al.  Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAs in hematopoietic precursor cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A. Frey,et al.  Tumor-Infiltrating Macrophages Induce Apoptosis in Activated CD8+ T Cells by a Mechanism Requiring Cell Contact and Mediated by Both the Cell-Associated Form of TNF and Nitric Oxide1 , 2001, The Journal of Immunology.

[9]  Hans J. Stauss,et al.  Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer , 2001, Nature Immunology.

[10]  A. Diefenbach,et al.  Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity , 2001, Nature.

[11]  G. Adams,et al.  High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. , 2001, Cancer research.

[12]  Ennis,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[13]  I. Weissman,et al.  Inactivation of a GFP retrovirus occurs at multiple levels in long-term repopulating stem cells and their differentiated progeny. , 2000, Blood.

[14]  P. Richardson,et al.  Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer , 2000, Bone Marrow Transplantation.

[15]  M. Reddish,et al.  Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE® STn-KLH cancer vaccine , 2000, Bone Marrow Transplantation.

[16]  P. Ricciardi-Castagnoli,et al.  Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo , 1999, Nature Medicine.

[17]  W. Nichols,et al.  High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer , 1998, Bone Marrow Transplantation.

[18]  R. Levy,et al.  Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. , 1998, Blood.

[19]  S. Rosenberg,et al.  A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-γ chain chimeric receptor gene recognizing a human ovarian cancer antigen , 1998, Nature Medicine.

[20]  Simon C Watkins,et al.  Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1. , 1998, Journal of immunology.

[21]  C. Janeway,et al.  Innate Immunity: The Virtues of a Nonclonal System of Recognition , 1997, Cell.

[22]  F. Appelbaum,et al.  High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer , 1997, Bone Marrow Transplantation.

[23]  David A. Williams,et al.  Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells , 1996, Nature Medicine.

[24]  J. Fontenot,et al.  Structure of a tumor associated antigen containing a tandemly repeated immunodominant epitope. , 1995, Journal of biomolecular structure & dynamics.

[25]  Peter A. Kollman,et al.  AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules , 1995 .

[26]  J. Bell,et al.  Selection of T cell receptor variable gene‐encoded amino acids on the third binding site loop: a factor influencing variable chain selection in a T cell response , 1995, European journal of immunology.

[27]  D. Hafler,et al.  Functional three-domain single-chain T-cell receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  N. Shastri,et al.  LacZ inducible, antigen/MHC-specific T cell hybrids. , 1994, International immunology.

[29]  N. Tjandra,et al.  Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core. , 1993, Cancer research.

[30]  J. Ihle,et al.  Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients , 1993, The Lancet.

[31]  O. Finn,et al.  Specific and Effective T‐Cell Recognition of Cells Transfected with a Truncated Human Mucin cDNA , 1993, Annals of the New York Academy of Sciences.

[32]  J. Yewdell,et al.  Identification of human cancers deficient in antigen processing , 1993, The Journal of experimental medicine.

[33]  J. Li,et al.  Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Klausner,et al.  High-efficiency expression and solubilization of functional T cell antigen receptor heterodimers. , 1992, Science.

[35]  P. Kraulis.  A program to produce both detailed and schematic plots of protein structures , 1991 .

[36]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[37]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[38]  Eugene W. Myers,et al.  Basic local alignment search tool. Journal of Molecular Biology , 1990 .

[39]  J. Taylor‐Papadimitriou,et al.  A short sequence, within the amino acid tandem repeat of a cancer‐associated mucin, contains immunodominant epitopes , 1989, International journal of cancer.

[40]  M. Lan,et al.  Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[41]  T. Mak,et al.  Reconstitution of an active surface T3/T-cell antigen receptor by DNA transfer , 1985, Nature.

[42]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[43]  R. Debets,et al.  Genetic engineering of T cell specificity for immunotherapy of cancer. , 2003, Human immunology.

[44]  Anja Zander,et al.  Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation , 1997, Bone Marrow Transplantation.

[45]  E A Merritt,et al.  Raster3D: photorealistic molecular graphics. , 1997, Methods in enzymology.